116 related articles for article (PubMed ID: 21614470)
1. Hematologic adverse events associated with temozolomide.
Villano JL; Letarte N; Yu JM; Abdur S; Bressler LR
Cancer Chemother Pharmacol; 2012 Jan; 69(1):107-13. PubMed ID: 21614470
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide-related hematologic toxicity.
Scaringi C; De Sanctis V; Minniti G; Enrici RM
Onkologie; 2013; 36(7-8):444-9. PubMed ID: 23921765
[TBL] [Abstract][Full Text] [Related]
3. Analyzing temozolomide medication errors: potentially fatal.
Letarte N; Gabay MP; Bressler LR; Long KE; Stachnik JM; Villano JL
J Neurooncol; 2014 Oct; 120(1):111-5. PubMed ID: 25026995
[TBL] [Abstract][Full Text] [Related]
4. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Gupta T; Mohanty S; Moiyadi A; Jalali R
Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Dixit S; Baker L; Walmsley V; Hingorani M
Anticancer Drugs; 2012 Nov; 23(10):1099-106. PubMed ID: 22850321
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of glioma with temozolomide].
Nishikawa R
Brain Nerve; 2009 Jul; 61(7):849-54. PubMed ID: 19618863
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
Riccardi A; Mazzarella G; Cefalo G; Garrè ML; Massimino M; Barone C; Sandri A; Ridola V; Ruggiero A; Mastrangelo S; Lazzareschi I; Caldarelli M; Maira G; Madon E; Riccardi R
Cancer Chemother Pharmacol; 2003 Dec; 52(6):459-64. PubMed ID: 13680160
[TBL] [Abstract][Full Text] [Related]
9. An analysis of temozolomide-related adverse drug reactions reported to the medicines and healthcare products regulatory agency through the yellow card scheme aiming to characterise idiosyncratic profound bone marrow suppression tantamount to aplastic anaemia.
Dixit S; Hingorani M; Allgar V
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):120-1. PubMed ID: 24183933
[No Abstract] [Full Text] [Related]
10. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Su YB; Sohn S; Krown SE; Livingston PO; Wolchok JD; Quinn C; Williams L; Foster T; Sepkowitz KA; Chapman PB
J Clin Oncol; 2004 Feb; 22(4):610-6. PubMed ID: 14726505
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient.
Chou KN; Lin YC; Liu MY; Chang PY
J Clin Neurosci; 2014 Apr; 21(4):701-4. PubMed ID: 24291476
[TBL] [Abstract][Full Text] [Related]
14. Non-Hodgkin lymphoma following temozolomide.
Sharma A; Gupta D; Mohanti BK; Thulkar S; Dwary A; Goyal S; Muzumder S; Das P
Pediatr Blood Cancer; 2009 Oct; 53(4):661-2. PubMed ID: 19533661
[TBL] [Abstract][Full Text] [Related]
15. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Khasraw M; Bell D; Wheeler H
J Clin Neurosci; 2009 Jun; 16(6):854-5. PubMed ID: 19303779
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
van den Bent MJ; Taphoorn MJ; Brandes AA; Menten J; Stupp R; Frenay M; Chinot O; Kros JM; van der Rijt CC; Vecht ChJ; Allgeier A; Gorlia T;
J Clin Oncol; 2003 Jul; 21(13):2525-8. PubMed ID: 12829671
[TBL] [Abstract][Full Text] [Related]
17. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide-induced aplastic anaemia: Case report and review of the literature.
Gilbar PJ; Pokharel K; Mangos HM
J Oncol Pharm Pract; 2021 Jul; 27(5):1275-1280. PubMed ID: 33086908
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of extended-dose temozolomide in patients with melanoma.
Rietschel P; Wolchok JD; Krown S; Gerst S; Jungbluth AA; Busam K; Smith K; Orlow I; Panageas K; Chapman PB
J Clin Oncol; 2008 May; 26(14):2299-304. PubMed ID: 18467721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
